scholarly journals Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis

2021 ◽  
pp. FSO717
Author(s):  
Hongbo Ma ◽  
Ailian Hei ◽  
Ji Zhou ◽  
Ellen He ◽  
Sven Skog ◽  
...  
Keyword(s):  
Thymidine Kinase ◽  
Transarterial Chemoembolization ◽  
Protein Concentration ◽  
Meta Analysis ◽  
Hepatic Hemangioma ◽  
Thymidine Kinase 1 ◽  
Hepatocellular Carcinomas ◽  
B Virus ◽  
Early Progression ◽  
Serum Thymidine Kinase 1

Aim: A meta-analysis was conducted to evaluate the clinical significance of serum thymidine kinase 1 protein concentration (STK1p) in distinguishing between hepatocellular carcinomas (HCC) and non-HCC for predicting early progression and monitoring the response to transarterial chemoembolization in HCC. Material & methods: A total of 24 eligible studies were included, containing 1849 HCC patients and 1069 healthy subjects. Results: The STK1p level significantly increased from normal controls to benign/pre-HCC and HCC (p < 0.0001). STK1p also increased significantly in sub-malignant groups: control being the lowest, followed consecutively by hepatic hemangioma, hepatitis B virus infection and hepatic cirrhosis (p < 0.05). After 1 month of transarterial chemoembolization treatment, STK1p level declined significantly, by 44.4% (p < 0.0001). Conclusion: STK1p is a useful prognostic biomarker in HCC.

scholarly journals Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer

ESMO Open ◽  
2021 ◽  
Vol 6 (2) ◽  
pp. 100076
Author(s):  
A. Matikas ◽  
K. Wang ◽  
E. Lagoudaki ◽  
B. Acs ◽  
I. Zerdes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Thymidine Kinase ◽  
Early Breast Cancer ◽  
Prognostic Role ◽  
Thymidine Kinase 1 ◽  
Serum Thymidine Kinase 1

scholarly journals High Serum Thymidine Kinase 1 Level Predicts Poorer Survival in Patients With Chronic Lymphocytic Leukemia

2010 ◽  
Vol 134 (3) ◽  
pp. 472-477 ◽  
Author(s):  
Sergej N. Konoplev ◽  
Herbert A. Fritsche ◽  
Susan O’Brien ◽  
William G. Wierda ◽  
Michael J. Keating ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Thymidine Kinase ◽  
High Serum ◽  
Lymphocytic Leukemia ◽  
Thymidine Kinase 1 ◽  
Serum Thymidine Kinase 1

Usefulness of Serum Thymidine Kinase 1 as a Biomarker for Aggressive Clinical Behavior in B-cell Lymphoma

2016 ◽  
Vol 6 (1) ◽  
pp. 25
Author(s):  
Heyjin Kim ◽  
Hye Jin Kang ◽  
Jin Kyung Lee ◽  
Young Jun Hong ◽  
Seok-Il Hong ◽  
...  
Keyword(s):  
B Cell ◽  
Thymidine Kinase ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Thymidine Kinase 1 ◽  
Clinical Behavior ◽  
Aggressive Clinical Behavior ◽  
Serum Thymidine Kinase 1

Application of Serum Thymidine Kinase-1 in Cancer Risk Detection in Healthy Population

2019 ◽  
Vol 11 (12) ◽  
pp. 1734-1738
Author(s):  
Jihong Xiao ◽  
Yufei Zhao ◽  
Chun Zhang
Keyword(s):  
Cancer Risk ◽  
Physical Examination ◽  
Thymidine Kinase ◽  
Normal Group ◽  
Benign Tumors ◽  
Thymidine Kinase 1 ◽  
Male And Female ◽  
Risk Detection ◽  
Significant Difference ◽  
Serum Thymidine Kinase 1

The purpose of this study was to evaluate the application of serum thymidine kinase 1 (STK1) in cancer risk detection in health general investigation. Using the method of dot-blot immunofluorescence enhancement, the data of STK1 of 12600 people were selected, and were carried out simultaneously with routine physical examination items. The results showed that the positive rate of STK1 (STK1> 2 pmol/L) was 2.10% with 2 pmol/L as the threshold, and the positive rates of male and female were 2.01% and 2.19%, respectively. There was no significant difference between male and female (χ2 = 0.46, P > 0.05). Compared with other age groups, both male and female between 40–59 years old had the highest detection rate in the age group of STK1 elevation, and twelve cases of malignant tumors were detected in the group of STK1 elevation, accounting for 4.55%. Compared with the normal group, it has significant significance. In the cases of benign tumors/cell dysplasia, 2194 cases detected were in normal group (17.78%) and 120 cases were in elevated group (45.45%). There was significant difference between normal group and elevated group (χ2 = 74.44, P < 0.01). There was no significant difference between the normal group and the elevated group in inflammatory, viral, fatty liver disease, other diseases and no special clinical conditions (P > 0.05). In the screening of cancer risk of general health investigation, STK1 can be applied to truly evaluate the abnormal proliferation of cells in vivo, and to screen a variety of tumors. It is suitable for early cancer risk screening of physical examination population.

Sign in / Sign up

Export Citation Format

Share Document